For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Anti-obesity drugs are only part of the larger treatment plan for most patients. Exercise and nutrition are also keys.

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

While the exact number of people with chronic kidney disease in South Africa is unclear, estimates suggest it could be as ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...